Release Date: November 26, 2025
Expiration Date: November 26, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned retina specialists to discuss the treatment of macular telangiectasia (MacTel) type 2, which is a rare, progressive retinal disease. In this educational program, these experts discuss recent innovations in approved therapy for this condition and opportunities for early detection and diagnosis.
This educational activity is an archive of the live symposium held on October 18, 2025.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, optometrists, and other eye care professionals involved in the management of patients with macular telangiectasia type 2.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify the limitations of anti-VEGF intravitreal injection therapies in the treatment of MacTel.
- Analyze emerging evidence supporting the use of novel therapies in the management of MacTel.
- Summarize the role of retina specialists in the optimal management of MacTel.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here